The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial

Obesity Research
F PedrinolaG Medeiros-Neto

Abstract

Current evidence demonstrates that pharmacologic agents, alone or in combination produce short-term weight-loss and may remain effective for extended periods of time in obese patients. We have evaluated the weight loss of a selective inhibitor of serotonin uptake, fluoxetine, alone as compared with combined therapeutic trial with another serotoninergic drug, dexfenfluramine. Thirty-three patients were randomly assigned in a double-blind randomized clinical trial divided to two groups: Group I [Fluoxetine 40 mg and placebo (n = 13)] and Group II [Fluoxetine 40 mg plus dexfenfluramine 15 mg at night (n = 20)]. Both groups had a significant weight loss at the end of 8 months (Group I, mean +/- SEM 6.2 +/- 2.8 kg and Group II 13.4 +/- 6.3 kg, p < 0.05). Group II patients had a significantly greater weight loss as compared with Group I both in terms of mean weight loss in kg and BMI in kg/m2. However significance between Group I and II related to BMI mean values and weight mean values were only achieved after, respectively, 4 and 6 months of treatment. At laboratory level there was an elevation of HDL-cholesterol and lowering of serum lipids values (cholesterol and triglycerides) in both groups. Side effects were relatively minor an...Continue Reading

References

May 1, 1992·Diabetic Medicine : a Journal of the British Diabetic Association·K A WilleyD K Yue
Aug 1, 1992·Journal of the American College of Cardiology·D D SchockenE A Ross
Feb 1, 1992·The American Journal of Clinical Nutrition·G A Colditz
Jul 15, 1991·Annals of Internal Medicine·G A Bray
Aug 1, 1991·The American Journal of Clinical Nutrition·L L DargaC P Lucas
Jul 1, 1991·Clinical Endocrinology·R T Jung, P Chong
Nov 11, 1989·Lancet·B Guy-GrandP Turner
Oct 1, 1994·Oral Surgery, Oral Medicine, and Oral Pathology·G E KaugarsJ Gallo
Aug 1, 1994·The American Journal of Clinical Nutrition·R L Atkinson, V S Hubbard
Nov 17, 1994·The New England Journal of Medicine·L Gram
Nov 1, 1995·Obesity Research·R L AtkinsonR A Lutes
Mar 1, 1993·Obesity Research·D J GoldsteinL A Fludzinski

❮ Previous
Next ❯

Citations

Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Richard B Rothman, Michael H Baumann
Aug 7, 2002·Pharmacology & Therapeutics·Richard B Rothman, Michael H Baumann
Aug 30, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·R Sherafat-KazemzadehJ A Yanovski
Jun 28, 2005·Drugs·Lisa L Ioannides-DemosJohn J McNeil
Mar 26, 2014·International Journal of Obesity : Journal of the International Association for the Study of Obesity·P T KatzmarzykJ A Yanovski
Jun 16, 2006·Expert Opinion on Drug Safety·Roger S McIntyreSidney H Kennedy
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Vincent Setola, Bryan L Roth
Jan 5, 2011·Journal of Obesity·Lisa L Ioannides-DemosJohn J McNeil
Jan 28, 2005·The Cochrane Database of Systematic Reviews·S L NorrisJ Lau
Dec 22, 1999·Endocrine Reviews·G A Bray, F L Greenway
Oct 16, 2019·The Cochrane Database of Systematic Reviews·Aurora E Serralde-ZúñigaGuillermo Melendez
Feb 2, 1999·Journal of Medicinal Chemistry·C P Kordik, A B Reitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.